Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 6.6% – Should You Sell?

Autolus Therapeutics plc (NASDAQ:AUTL)’s stock price was down 6.6% on Thursday . The stock traded as low as $2.71 and last traded at $2.71. Approximately 905,169 shares changed hands during mid-day trading, a decline of 38% from the average daily volume of 1,465,235 shares. The stock had previously closed at $2.90.

Analysts Set New Price Targets

Several analysts have weighed in on AUTL shares. The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the company from $7.00 to $7.60 in a report on Monday, November 18th. Needham & Company LLC reiterated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Thursday, December 5th. Finally, Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective on the stock in a research report on Friday, November 15th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Autolus Therapeutics has an average rating of “Buy” and a consensus target price of $10.40.

Autolus Therapeutics Stock Performance

The stock has a market capitalization of $729.09 million, a P/E ratio of -2.40 and a beta of 1.99. The firm has a 50-day moving average price of $3.63 and a 200 day moving average price of $3.86.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period last year, the company posted ($0.26) earnings per share. On average, equities analysts anticipate that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP grew its position in Autolus Therapeutics by 35.4% during the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock worth $87,919,000 after acquiring an additional 6,330,392 shares during the last quarter. State Street Corp grew its position in Autolus Therapeutics by 1.7% during the 3rd quarter. State Street Corp now owns 606,544 shares of the company’s stock worth $2,202,000 after acquiring an additional 10,401 shares during the last quarter. HighVista Strategies LLC grew its position in Autolus Therapeutics by 2.7% during the 3rd quarter. HighVista Strategies LLC now owns 533,024 shares of the company’s stock worth $1,935,000 after acquiring an additional 14,204 shares during the last quarter. Erste Asset Management GmbH bought a new position in Autolus Therapeutics during the 3rd quarter worth approximately $708,000. Finally, Bellevue Group AG grew its position in Autolus Therapeutics by 27.7% during the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock worth $151,000 after acquiring an additional 9,000 shares during the last quarter. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.